UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more
UCB SA (UCBJF) - Total Assets
Latest total assets as of December 2025: $18.15 Billion USD
Based on the latest financial reports, UCB SA (UCBJF) holds total assets worth $18.15 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
UCB SA - Total Assets Trend (2002–2025)
This chart illustrates how UCB SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
UCB SA - Asset Composition Analysis
Current Asset Composition (December 2025)
UCB SA's total assets of $18.15 Billion consist of 33.3% current assets and 66.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.4% |
| Accounts Receivable | $1.79 Billion | 9.8% |
| Inventory | $1.50 Billion | 8.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.45 Billion | 19.0% |
| Goodwill | $5.09 Billion | 28.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how UCB SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: UCB SA's current assets represent 33.3% of total assets in 2025, a decrease from 66.1% in 2002.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, down from 18.4% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 9.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 28.0% of total assets.
UCB SA Competitors by Total Assets
Key competitors of UCB SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
UCB SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - UCB SA generates 0.43x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, UCB SA generates $8.58 in net profit.
UCB SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 1.36 | 1.27 |
| Quick Ratio | 1.04 | 0.99 | 0.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.65 Billion | $ 1.26 Billion | $ 768.00 Million |
UCB SA - Advanced Valuation Insights
This section examines the relationship between UCB SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.75 |
| Latest Market Cap to Assets Ratio | 1.12 |
| Asset Growth Rate (YoY) | 4.6% |
| Total Assets | $18.15 Billion |
| Market Capitalization | $20.38 Billion USD |
Valuation Analysis
Above Book Valuation: The market values UCB SA's assets above their book value (1.12 x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: UCB SA's assets grew by 4.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for UCB SA (2002–2025)
The table below shows the annual total assets of UCB SA from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $18.15 Billion | +4.64% |
| 2024-12-31 | $17.35 Billion | +11.64% |
| 2023-12-31 | $15.54 Billion | -2.07% |
| 2022-12-31 | $15.87 Billion | +11.67% |
| 2021-12-31 | $14.21 Billion | +6.69% |
| 2020-12-31 | $13.32 Billion | +20.20% |
| 2019-12-31 | $11.08 Billion | +5.39% |
| 2018-12-31 | $10.51 Billion | +6.02% |
| 2017-12-31 | $9.92 Billion | -2.89% |
| 2016-12-31 | $10.21 Billion | -6.79% |
| 2015-12-31 | $10.96 Billion | +7.96% |
| 2014-12-31 | $10.15 Billion | +2.43% |
| 2013-12-31 | $9.91 Billion | +5.84% |
| 2012-12-31 | $9.36 Billion | +1.98% |
| 2011-12-31 | $9.18 Billion | +2.33% |
| 2010-12-31 | $8.97 Billion | -1.66% |
| 2009-12-31 | $9.12 Billion | -4.24% |
| 2008-12-31 | $9.52 Billion | -0.32% |
| 2007-12-31 | $9.55 Billion | -8.98% |
| 2006-12-31 | $10.50 Billion | +122.56% |
| 2005-12-31 | $4.72 Billion | -12.22% |
| 2004-12-31 | $5.37 Billion | +73.85% |
| 2003-12-31 | $3.09 Billion | +17.93% |
| 2002-12-31 | $2.62 Billion | -- |